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Abstract
Inflammation is a key element in many cardiovascular diseases. Both estrogen loss, caused by menopause, and aging have
inflammatory consequences. Epoxyeicosatrienoic acids (EETs) are anti-inflammatory molecules synthesized by various
cytochrome P450 (Cyp) enzymes from arachidonic acid. EETs are in the third (Cytochrome P450) pathway of arachindonic
acid metabolism, others being cyclooxygenases and lipoxygenases. We hypothesized that aging and estrogen loss would
reduce levels of anti-inflammatory EETs. Adult (6 mo) and aged (22 mo) ovariectomized rats with (OP) and without (Ovx) 17-
’-estradiol replacement were used in this study. Mass spectrometry was used to measure levels of EETs and their
metabolites, dihydroxyeicosatrienoic acids (DHETs). Levels of Cyp2C2, Cyp2C6, and Cyp2J2, the principal Cyps responsible
for EETs synthesis, as well as soluble epoxide hydrolase (sEH), which metabolizes EETS to DHETs, were determined via
western blot. Overall Cyp levels decreased with age, though Cyp2C6 increased in the liver. sEH was increased in the kidney
with estrogen replacement. Despite protein changes, no differences were measured in plasma or aortic tissue levels of EETs.
However, plasma 14,15 DHET was increased in aged Ovx, and 5,6 DHET in adult OP. In conclusion neither aging nor estrogen
loss decreased the anti-inflammatory EETs in the cardiovascular system.
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Introduction
Menopause is characterized by dramatically decreased estrogen
levels and a marked acceleration of atherosclerosis and heart
disease in women [1]. Although a loss of estrogen is blamed for
these effects and a number of animal studies support this [2,3],
clinical studies showed no benefit from hormone replacement
treatment(HRT) for post-menopausal females [4,5]. In fact,
although nonrandomized studies had supported that HRT was
cardio-protective for women post-menopause, the randomized,
double-blinded clinical trials showed an increase in cardiovascular
events, particularly during the first year of treatment. Further
analysis of these results led to the timing hypothesis [6], that a long
delay between menopause and HRT was a factor in the increased
cardiovascular disease in the trials. Recent work from our lab
indicates that delayed estrogen administration leads to an increase
in inflammatory gene expression [7], signifying that inflammation
plays a role in the deleterious effects seen with late estrogen
administration in the clinical trials. Because inflammatory changes
have been definitively associated with the development of
atherosclerosis [8,9], the identification of antioxidant and anti-
inflammatory pathways and molecules has become paramount.
There are three arachidonic acid metabolism pathways: the
COX (cycloxygenase) pathway, the LOX (lipoxygenase) pathway
and the CYP (cytochrome P450) pathway. The importance of the
first two pathways, which produce prostaglandins and leukotri-
enes, is well-established in the cardiovascular system; however, the
role of the CYP pathway, which produces epoxyecosatrienoic
acids (EETs), has yet to be fully characterized. EETs, of which
there are 4 isoforms (5,6-, 8,9-, 11,12-, and 14,15-), are lipid
signaling molecules synthesized primarily by the action of 2
families of cytochrome P450 (Cyp) enzymes, Cyp2C and Cyp2J,
on arachadonic acid [10]. Recent evidence indicates that EETs act
as important anti-inflammatory and antioxidant molecules
[10,11]. EETs have been shown to protect against ischemic injury
by reducing inflammation [12], and have important stimulatory
effects on angiogenesis [13]. EETs are predominantly metabolized
by soluble epoxide hydrolase (sEH) into their corresponding
dihydroxyeicosatrienoic acid (DHET) isoforms (Figure 1). While
other epoxide hydrolases are of little importance in EET
metabolism, other metabolic pathways, such as ’-oxidation, T-
oxidation and chain elongation, are of some importance,
particularly when sEH is suppressed [14–16]. sEH polymorphisms
are associated with an increased risk in atherosclerosis in a number
of clinical studies [17–19], and treatment of apolipoprotein E
knockout mice with synthesized sEH inhibitors for 8 weeks
reduced atherosclerosis in these animals [20]. The function of
DHETs is less clear, as early studies showed injurious effects, but
later ones are not definitive on this issue [21,22]. Because a
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number of potential therapeutic agents have been developed that
inhibit sEH, we were interested if aging and estrogen loss, which
are associated with increased inflammation, alter the expression of
EETs or the enzymes involved in their synthesis and degradation.
Inhibition of sEH to increase expression of the anti-inflammatory
EETs has the potential to be a therapeutic approach to ameliorate
some of the adverse changes of aging.
Materials and Methods
Animal Model
Norway-Brown rats , 4–6 months [Adult] and 19–22 months
[Aged] of aged, were obtained from the National Institutes on
Aging (Bethesda, MD), housed in standard female only conditions,
and fed standard laboratory rat chow. All rats underwent
ovariectomy (ovx) and half received 17’-estradiol (E2) replace-
ment using a 0.5 mg E2 sustained release capsule (Innovative
Research, Sarasota, FL) implanted at the time of ovx, as previously
described [7,23]. Rats were divided into 4 groups (Adult Ovx,
Adult ovx with immediate estrogen replacement [Adult OP], Aged
Ovx, and Aged ovx with immediate estrogen replacement [Aged
OP]). Tissue collection was done 9 weeks post ovariectomy based
on our findings that following ovariectomy there appears to be a
cascade of changes over at least a 9 week period, and that this
amount of time is required for cardiac levels of heat shock protein
72 to decline to levels seen in males [24]. All samples were
collected at the same time of day. Plasma samples and the liver,
kidney, left ventricle, aorta and uterus were collected at 9 weeks,
flushed with ice-cold PBS and flash frozen in liquid nitrogen. At
the time of tissue collection, the uterus was weighed to verify
treatment groups. All animal protocols were approved by the
University of California, Davis Animal Research Committee in
accordance with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals.
Liquid Chromatography/Mass Spectrometry for oxylipin
profiling analysis - Plasma sample preparation
Plasma samples were spiked with 10: L 500 nM internal
standard I (d4-6-keto-PGF1a, d4-PGE2, d4-TXB2, d4-LTB4,
d11-14,15-DiHETrE, d6-20-HETE, d4-9-HODE, d8-12-HETE,
d8-5-HETE, d11-11(12)-EpETrE, d4-9(10)-EpOME, d8-AA) and
then were extracted by solid phase extraction using Oasis HLB
cartridges (3cc 60mg, Waters, Milford, MA). The HLB cartridges
were first washed with 2 mL ethyl acetate, 2 mL methanol twice,
and 2 mL 95:5 v/v water/methanol with 0.1% acetic acid. The 6
mL heart perfusate samples were then loaded in duplicates onto
the cartridges with 3 mL samples per cartridge. 10 :L of butylated
hydroxyl toluene (BHT) was added to each sample after loading.
The samples were then washed with 6 mL 95:5 v/v water/
methanol with 0.1% acetic acid and dried for 20 min with low
vacuum. The target analytes were then eluted with 0.5 mL
methanol followed by 2 mL of ethyl acetate into the tubes with 6
:L 30% glycerol in methanol as the trap solution. The volatile
solvents were evaporated by using vacuum centrifugation (Speed-
Vac) until 2 :L trap solution remained in the tube. The residues
were dissolved in 50 :L of methanol containing 200 nM internal
standards II (1-cyclohexyl-dodecanoic acid urea, CUDA). The
samples were mixed with a vortex mixer for 2 min, centrifuged at
14000 x g for 5 min and then transferred to auto sampler vials with
150 :L inserts for LC/MS/MS analysis.
Aorta sample preparation
Aortic tissues (25–50 mg) were collected, flash-frozen in liquid
nitrogen and stored at 220uC for extraction. After weighing, the
aorta samples were spiked with 10 :L 500 nM internal standard I
as described above. 400 :L of ice-cold methanol with 0.1 % of
acetic acid and 0.1% of BHT were added onto tissue samples and
samples were incubated at 220uC for 30 min. Samples were then
homogenized at 30 Hz for 30 min and stored at 220uC freezer
overnight. The supernatants were collected after centrifugation at
10,000 rpm for 10 min. The remaining pellets were washed with
Figure 1. Diagram summarizes key steps in EETs synthesis and metabolism.
doi:10.1371/journal.pone.0070719.g001
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100 :L of ice-cold methanol with 0.1 % of acetic acid and 0.1% of
BHT and centrifuged. The supernatants of each sample were
combined and diluted with 2 mL of H2O and load onto SPE
cartridges. Further sample preparation was as described for
plasma sample preparation.
LC/MS/MS Analysis
Liquid chromatography/tandem MS (LC/MS/MS) analysis of
oxylipins was performed using a modified method based on the
previous publication [25]. An Agilent 1200 SL liquid chromatog-
raphy series (Agilent Corporation, Palo Alto, CA) with an Agilent
Eclipse Plus C18 2.1 x 150 mm, 1.8 :m column was used for the
oxylipins separation. The mobile phase A was water with 0.1%
acetic acid while the mobile phase B was composed of acetonitrile/
methanol (80/15, v/v) and 0.1% acetic acid. Gradient elution was
performed at a flow rate of 250 :L/min and the gradient used is
described in Table 1. The injection volume was 10 :L and the
samples were kept at 4uC in the auto sampler. Analytes were
detected by negative MRM mode using a 4000 QTrap tandem
mass spectrometer (Applied Biosystems Instrument Corporation,
Foster City, CA) equipped with an electrospray ionization source
(Turbo V). The QTrap was set as follows: CUR = 20 psi, TEM
= 500uC, GS1 = 50 psi, GS2 = 30 psi, CAD = High, IS
=24500 V, DP =260 V, EP =210 V. Calibration curves were
generated by 10 :L injections of seven standards containing each
analyte, internal standard I, and internal standard II for
quantification purpose. The EETs levels represent free EETs.
Western blot analysis
Analysis was performed as previously described [26]. Prior to
analysis, albumin was removed from the liver samples, as the
abundant amount of this protein interfered with analysis of other
proteins of similar size. Samples from a 3:1 mixture with Affi-gel
blue (Bio-Rad, Hercules, CA) were agitated for 30 minutes at 4u C
and briefly centrifuged to remove the Affi-gel blue which is cross-
linked to agarose beads. The supernatant was used for analysis of
liver protein expression. All other tissues were processed in a
standard manner as previously described [26]. Antibodies were
used in the following dilutions: Cyp2C2 (Santa Cruz, Santa Cruz,
CA) 1:1000; Cyp2C6 (Santa Cruz) 1:1000; Cyp2J2 (Santa Cruz)
1:1000; sEH (Cayman Chemicals, Ann Arbor, MI) 1:1000. The
appropriate HRP-conjugated secondary antibodies of anti-mouse
or anti-rabbit (GE, UK) were used at 1:1000 dilutions and
developed using West Pico enhanced chemiluminescence (Thermo
Scientific, Waltham, MA). Proteins were normalized to GAPDH,
which did not vary among groups. When separate gels were run
for multiple samples, internal normalization controls were used in
order to accurately compare the gels.
Data analysis
Results are presented as the mean +/2 SEM of at least three
separate experiments. Data were analyzed by a one-way ANOVA
or an ANOVA on Ranks, followed by a Student Neuman Keuls
test or Dunn’s test, where appropriate. A p , 0.05 was considered
significant (Sigma Stat).
Results
Plasma EETs levels (the four isomers) did not differ based on
either age or estrogen status (Fig. 2A). In contrast, the DHETs
showed some marked differences (Fig. 2B). The 14,15-DHET
levels in the Aged Ovx group were higher than the other treatment
groups. The 5,6-DHETs in the aged OP group were lower than
those measured in the adult OP group. The plasma 11,12- and
8,9-DHET levels did not differ among the groups.
Three enzymes are reported as responsible for the majority of
EETs synthesis - Cyp2J2, Cyp2C2, and Cyp2C6 (rat equivalent to
human enzymes 2J2, 2C8 and 2C9). Soluble epoxide hydrolase
(sEH) metabolizes EETs to DHETs and is the principal route of
EETs metabolism. The major sources of EETs are the liver and
kidney [10]. As seen in Figure 3A, liver levels of Cyp2C2 and
Cyp2J2 decreased in the Aged OP group, with Cyp2C2
significantly less (p,0.05) than all other groups, and Cyp2J2
significantly less (p,0.05) compared to Adult OP. In contrast,
Cyp2C6 was increased significantly (p,0.05) in both Aged groups
compared to Adult OP. The sEH levels in the liver were
unchanged with estrogen (E2) treatment or age (Fig. 3B). In
contrast to the liver, renal Cyp2C2 and Cyp2J2 levels were
unaltered with age or E2 (Fig. 3C), while Cyp2C6 was elevated
Adult Ovx and Aged OP compared to Adult OP (p,0.05). The
sEH levels increased in both E2 treated groups compared to Adult
Ovx (Figure 3D; p,0.05).
Significant vascular changes occur with aging and estrogen loss
include increased stiffness, impaired relaxation and increased
atherosclerosis [26,27]. Aortic levels of Cyp2C2, Cyp2C6 and
Cyp2J2 did not vary with age or E2 treatment (Fig. 4A), and the
levels of sEH in the aorta were similarly constant (Fig. 4B). In the
left ventricle, Cyp2C6 decreased in both Aged groups compared to
Adult OP (p ,0.05), and Cyp2C2 protein levels decreased in the
Aged OP groups compared to Adult Ovx. Cyp2J2 and sEH levels
in the left ventricle were unchanged (Fig. 5). Because tissue levels
of substances can differ markedly from the plasma levels, we
investigated aortic levels of EETs. Tissue levels of EETs did not
vary with estrogen or aging for any of the isoforms (Fig. 6).
Discussion
Levels of Cyp epoxygenases varied in some tissues with aging
and estrogen status. Generally, aging led to a decrease in Cyp
protein levels, though an increase was seen in liver Cyp 2C6 level.
sEH levels, by contrast, varied only in the kidney, based on
estrogen status, with both OP groups showing increased amounts
of sEH. The measured plasma levels of EETs, however, did not
vary among groups.
Table 1. LC Mobile Phase Gradient.
Total Time Flow Rate A (%) B (%)
(min) (:L/min)
0 250 65 35
0.25 250 65 35
1 250 55 45
3 250 45 55
8.5 250 34 66
12.5 250 28 72
15 250 18 82
16.5 250 5 95
18 250 5 95
18.1 250 65 35
21.5 250 65 35
Details of elution gradient.
doi:10.1371/journal.pone.0070719.t001
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EETs Synthesis
EETs are formed by the metabolism of arachidonic acid by
cytochrome P450 epoxygenases. In humans, the major Cyps
reported to be responsible for EET synthesis are 2C8, 2C9 and
2J2, corresponding to Cyps 2C2, 2C6 and 2J2 in the rat [28,29].
The principal sources of circulating EETs are reported to be the
liver and kidneys [10]. In the liver, aging led to decreased
expression of Cyp2C2 and 2J2 and an increase in Cyp2C6. This
increase in Cyp2C6 was mirrored in the kidney. EET levels are
determined not just by production via the Cyp’s, but also by
metabolism to DHETs by sEH. Aging had no effect on sEH levels
in the liver or kidney; estrogen replacement, however, lead to
increased levels of sEH compared to Adult Ovx, as expected from
murine studies [30]. Predicting how plasma levels of EETs should
vary based on protein expression is complicated by this variation
in Cyp and sEH levels. However, the measured plasma levels
showed no significant differences in any of the four isomers with
either aging or estrogen status. It seems reasonable that there is no
change in total EETs given the various increases and decreases in
protein levels. It is interesting however, that there is no significant
change in the distribution of EET isomers to go along with these
changes, given that the different Cyp enzymes can form all of the
isomers, but have some level of selectivity [14,31]. Given that
EETs levels do not vary significantly with age or estrogen status,
levels of DHETs should largely be dependent principally upon
sEH metabolism of the corresponding EETs. The only differences
seen were an increase in 14,15 DHET in aged ovx and an increase
in 5,6 DHET in adult OP. The only groups with increased sEH
expression were adult and aged OP.
The oxylipins measured are free fatty acid oxylipins which have
been widely used as biomarkers of biologically active fatty acid
chemical mediators [32–35]. Given that over 90% of the plasma
EETs was esterified to the phospholipids of circulating lipopro-
teins, it is expected that the downstream effect of these plasma
metabolites will be influenced by shifts in lipoprotein metabolism
[35,35–37]. The plasma oxylipin levels may not reflect the levels of
oxylipins in different tissues, in different plasma fractions, or the
oxylipins sequestered as phospholipids and other esters; however,
free EETs are thought to be the major biologically active form,
with phospholipid EETs being a storage or inactive form. There is
little information concerning whether the EETs and other
eicosanoids in the phospholipids represent the major pools and
generally what conditions mobilize the EETs. In multiple previous
studies, the correlation of plasma lipid mediators with biologic
activities has proven accurate [32–35].
Plasma EETs levels - were generally highest in the aged ovx, but
this did not reach significance. In contrast, 14,15 DHET levels
were clearly increased in aged ovx. Our average values for the
various EET isoforms among the groups was 2–8 nM. This is not
inconsistent with other groups, however published values vary
significantly. Reported levels of 14,15 EET range from 0.3 to 13
nM (human), and 11,12 EET from 0.3 to 48.5 nM (mouse and rat)
[38–43]. Partly, this is due to differences in methodology. It can be
challenging to compare levels between and among papers, because
measurements often differ, for example measuring total EETs,
versus just 11,12 EET, or 14,15 EET. In addition, nearly all
previous studies examined only juvenile or young adult models.
With an interest in EETs as a possible therapeutic for
decreasing inflammation, we looked also at Cyp expression in
the heart (left ventricle) and vasculature (aorta). In the heart, Cyp
2C6 was decreased in both aged groups. Cyp 2C2 was decreased
in the Aged OP group, while Cyp 2J2 was unchanged. Neither
aging nor estrogen status effected sEH. The changes in Cyp and
sEH protein expression are similar to that in the liver.
Polymorphisms in Cyp2J2 are associated with increased risk of
coronary artery disease [44]. The polymorphism investigated in
this case led to a decrease in measured plasma DHETs levels.
While the decrease in Cyp2J2 in the liver measured with aging in
our study did not have a corresponding decrease in measured
EETs or DHETs, this relative loss of Cyp2J2 may contribute to an
increased risk of CAD and related diseases.
In contrast, no significant differences in any of the measured
proteins were detected in the aorta. Vascular (aortic tissue) levels of
EETs were measured, and, similar to plasma levels, found to have
no significant differences based on aging or estrogen status. These
levels reflect the lack of difference in protein expression among
groups.
Overall EETs are considered anti-inflammatory and beneficial.
EETs are anti-inflammatory and promote angiogenesis [14].
However there may be a downside to this, as a recent study using
adenovirus mediated overexpression of (human) Cyp 2C8 and Cyp
2J2, along with an sEH null, in mice, found increased tumor
metastasis [45]. The increased levels of EETs in these mice also
promoted tumor growth. Measured levels of EETs were approx-
imately 0.3 nM in the Cyp overexpressed mice and 4.2 nM for the
Figure 2. Plasma levels of EETs and DHETs from MS analysis. A:
EETs levels. B: DHETs levels. Adult Ovx- white bars, Adult OP- white bars
with pattern, Aged Ovx- grey bars, Aged OP- grey bars with pattern. #
P,0.05 compared with Adult OP, * P,0.001 compared with all. n = 6–8/
group for EETs; n = 5–8/group for DHETs, except 5,6 DHET where n = 3–
4/group.
doi:10.1371/journal.pone.0070719.g002
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sEH null mice, in a similar range to EETs levels reported in the
literature and this study, as discussed above.
EETs and Cardiovascular Protection
Most in vivo studies of EETs and cardiovascular protection have
used sEH inhibitors to increase EETs levels, given the short half-
life of EETs. Two studies involving vascular damage showed
benefit: one study showed decreased inflammatory markers, rate of
abdominal aortic aneurysm formation and atherosclerotic lesion
area, while another showed a decrease in neointima formation as
well as a decrease in smooth muscle proliferation and expression of
pro-inflammatory genes in a femoral cuff model [46,47]. However,
there was neither improved outcome with sEHi n following carotid
artery ligation, nor decreased macrophage adhesion with the
femoral cuff model [46,47]. EETs or sEHi treatment have a been
found to reduce infarct size and contribute to preconditioning
[48,49]. EETs also have been shown to reduce apoptosis in
neonatal rat cardiac myocytes after hypoxia/reoxygenation [50].
Interestingly, sEHi prevented stroke in spontaneously hypertensive
stroke-prone rats without reducing blood pressure [51]. Thus
EETs or sEHi have protective properties in the cardiovascular
system.
Knowledge of the normal levels of EETs in organisms can give
perspective on observed effects of EETs’ treatments in cell culture
as well as in vivo. There is great interest in EETs anti-inflammatory
and anti-apoptotic properties in cell and tissue injury. Dhanase-
karan et al. found 1 uM of 8,9-, 11,12-, or 13–15-EETs reduced
apoptosis after hypoxia/reoxygenation in HL-1 cells and in
neonatal cardiac myocytes [50]. EETs activated the pro-survival
pathway, PI3K/Akt. In another study, it was observed that 1 uM
11,12-EET increased sphingosine kinase-1(SK1) activity by 110%
[52]. 11,12-EETs also increased endothelial cell proliferation, and
Figure 3. Western blot analysis of liver and kidney EETs related genes, normalized to GAPDH. A representative Western blot showing
bands from each of the 4 groups in the order they are given on the graph plus a representative GAPDH blot are shown for each graph. A: Cyp2C2,
Cyp2J2 and Cyp2C6 in liver. B: sEH in liver. C: Cyp2C2, Cyp2J2 and Cyp2C6 in kidney. D: sEH in kidney. # P,0.05 compared with Adult OP, * P,0.05
compared with Adult Ovx; n = 9–11/group.
doi:10.1371/journal.pone.0070719.g003
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this was prevented by selective inhibition of SK1 [52]. Lipopoly-
saccharide (LPS) induces a strong pro-inflammatory response
including the production of inflammatory prostaglandins. In
monocytes, 10 uM 11,12 EET prevented increased PGE2 synthesis
after LPS treatment [53]. Concentrations of EETs in this set of
studies ranges from 1 uM to 10 uM. An important question is
whether the observed protective effects of EETs in these studies
represent basal activity or pharmacologic. In the current study we
found that plasma EETs levels are less than 10 nM for each of the
four EETs. Thus the observed protective effects in these studies
occurred with pharmacologic levels of EETs, and may not occur
with physiologic concentrations.
Arachidonic Acid Metabolism, Aging and Estrogen Loss
In the current study, EETs metabolism varied little with
estrogen loss and aging. In contrast, the cyclooxygenase pathway,
which can lead to the production of ROS as well as prostaglandins
and via COX-1 and 2 , has been found to change with aging and
estrogen loss [54]. Aging alone was found decrease arteriole
expression of COX-1, but not to affect COX-2 expression [55].
Figure 4. Western blot analysis of aorta EETs related genes,
normalized to GAPDH. A representative Western blot showing
bands from each of the 4 groups in the order they are given on the
graph plus a representative GAPDH blot are shown for each graph. A:
Cyp2C2, Cyp2J2 and Cyp2C6 in aorta. B: sEH in aorta. n = 6–9/group.
doi:10.1371/journal.pone.0070719.g004
Figure 5. Western blot analysis of left ventricle EETs related
genes, normalized to GAPDH. A representative Western blot
showing bands from each of the 4 groups in the order they are given
on the graph plus a representative GAPDH blot are shown for each
graph. A: Cyp2C2, Cyp2J2 and Cyp2C6 in LV. B: sEH in LV. # P,0.05
compared with Adult OP, * P,0.05 compared with Adult Ovx; n = 9–11/
group.
doi:10.1371/journal.pone.0070719.g005
Figure 6. Aortic levels of EETs fromMS analysis. Adult Ovx- white
bars, Adult OP- white bars with pattern, Aged Ovx- grey bars, Aged OP-
grey bars with pattern. n = 3–5/group.
doi:10.1371/journal.pone.0070719.g006
Aging and EETs
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Estrogen blocked increased expression of COX-2 in the vascula-
ture and inhibited increased production of PGE2 in response to
LPS and other stimuli [56,57]. This protective effect was lost with
aging. Similarly COX derived prostanoids and ROS increase with
aging and estrogen loss, contributing to vascular dysfunction [54].
Studies on the lipoxygenase (LO) metabolites of arachidonic acid
in aging and estrogen loss are very limited. In a single study,
pulmonary artery contractions were much greater in female than
male rabbits in response to LO arachidonic acid metabolites, and
this response was secondary to increased levels of 15-Hete [58].
This correlated with increased expression of 15-LO in female
rabbit arteries. Thus, overall there is an increase in pro-
inflammatory responses in the prostaglandin arm of arachidonic
acid metabolism with aging and loss of estrogen. In contrast, in the
current study EETs metabolism showed little variation with aging
and estrogen loss.
Limitations
In our studies we used standard rat chow, which often contains
significant amounts of soy protein and phytoestrogens. It is
possible that phytoestrogens’s estrogen-like properties may have
masked differences, even though our approach results in marked
differences in E2 levels amongst the groups and we have
consistently found differences in other studies using the same
model [26,59,60]. Serum samples were collected three different
times and there was variability amongst serum samples from the
same group (e.g. adult ovx) of rats housed together, eating the
same rat chow. Therefore, we think it unlikely that phytoestrogens
masked differences, but cannot completely exclude this possibility.
Some clear differences have been found with phytoestrogens in a
number of studies including a decrease in atherosclerosis in the
Apo E knockout mouse, decreased soluble vascular cell adhesion
protein (VCAM)-1, increased eNOS expression, increased anti-
oxidants and decreased monocyte chemo-attractant protein
(MCP) -1 [61–64]. In another study, MCP-1 did not change with
a soy supplemented diet [63]5611. Other studies with different
endpoints have found no or very limited phytoestrogen effects
[65,66]. In fact, many excellent labs have used standard rat chow
in their studies, again finding significant differences with changes
in estrogen [67–70]. Nonetheless, we cannot completely exclude
phytoestrogens in standard rat chow as contributing to the
variability in EETs levels, which is most apparent in the aged ovx
group.
We have investigated the major enzymes responsible for
circulating and cardiac levels of EETs and DHETs. While there
is no significant change in EETs levels with either aging or
estrogen status, there are some changes in Cyp protein expression.
Increased inflammation seen with aging, then, is not due to a loss
of circulating EETs and at least this arm of the arachidonic acid
metabolism pathway is preserved. While this means that the
inflammatory changes of aging and estrogen loss cannot be
decreased by replacement of lost EETs, they may nonetheless be
counterbalanced by increasing EETs levels beyond those naturally
produced, either with EETs supplementation or sEHi adminis-
tration. Further investigation of the in vivo effects of elevated EETs
levels are needed.
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